Drugs / EBV-LMP-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00078494 | Feb 2004 → May 2006 | nasopharyngeal neoplasm | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV-LMP-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00078494 ↗ |
| Modality | Vaccine | “experimental vaccine to prevent recurrence of nasopharyngeal cancer” NCT00078494 ↗ |
| Route | Subcutaneous | “The injections are given under the skin of the thigh.” NCT00078494 ↗ |